Literature DB >> 33876500

Programmed Size-Changeable Nanotheranostic Agents for Enhanced Imaging-Guided Chemo/Photodynamic Combination Therapy and Fast Elimination.

Guohui Cheng1, Wei Zong2,3, Haizhen Guo1, Fuyan Li2,3, Xu Zhang1, Peng Yu1, Fuxin Ren2,3, Xinlu Zhang1, Xiaoen Shi1, Fei Gao2,3, Jin Chang1, Sheng Wang1.   

Abstract

An ideal nanotheranostic agent should be able to achieve efficient tumor accumulation, retention, and fast elimination after its theranostic functions exhausts. However, there is an irreconcilable contradiction on optimum sizes for effective tumor retention and fast elimination. Herein, a programmed size-changeable nanotheranostic agent based on polyprodrug-modified iron oxide nanoparticles (IONPs) and aggregation-induced emission photosensitizer is developed for enhanced magnetic resonance imaging (MRI)-guided chemo/photodynamic combination therapy. The nano-sized theranostic agents with an initial diameter of about 90 nm can accumulate in tumor tissue through passive targeting. In the acidic tumor microenvironment, large aggregates of IONPs are formed, realizing enhanced tumor retention and MR signal enhancement. Under the guidance of MRI, light irradiation is applied to the tumor site for triggering the generation of reactive oxygen species and drug release. Moreover, after chemo/photodynamic combination therapy, the large-sized aggregates are re-dispersed into small-sized IONPs for fast elimination, reducing the risk of toxicity caused by long-term retention. Therefore, this study provides a promising size-changeable strategy for the development of nanotheranostic agents.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  fast elimination; magnetic resonance imaging; nanotheranostics; photodynamic therapy; polyprodrugs

Year:  2021        PMID: 33876500     DOI: 10.1002/adma.202100398

Source DB:  PubMed          Journal:  Adv Mater        ISSN: 0935-9648            Impact factor:   30.849


  6 in total

1.  pH-responsive hybrid platelet membrane-coated nanobomb with deep tumor penetration ability and enhanced cancer thermal/chemodynamic therapy.

Authors:  Huang Yang; Yuan Ding; Zongrui Tong; Xiaohui Qian; Hao Xu; Fenghao Lin; Guoping Sheng; Liangjie Hong; Weilin Wang; Zhengwei Mao
Journal:  Theranostics       Date:  2022-05-16       Impact factor: 11.600

Review 2.  Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery.

Authors:  Lingling Huang; Jianmiao Yang; Tiantian Wang; Jianqing Gao; Donghang Xu
Journal:  J Nanobiotechnology       Date:  2022-01-24       Impact factor: 10.435

3.  Tumor-specific activatable biopolymer nanoparticles stabilized by hydroxyethyl starch prodrug for self-amplified cooperative cancer therapy.

Authors:  Yuxuan Xiong; Zibing Wang; Qiang Wang; Qingyuan Deng; Jitang Chen; Jianshuang Wei; Xiaoquan Yang; Xiangliang Yang; Zifu Li
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

4.  Dual Targeting with Cell Surface Electrical Charge and Folic Acid via Superparamagnetic Fe3O4@Cu2-xS for Photothermal Cancer Cell Killing.

Authors:  Zicheng Deng; Jou Lin; Sergey L Bud'ko; Brent Webster; Tanya V Kalin; Vladimir V Kalinichenko; Donglu Shi
Journal:  Cancers (Basel)       Date:  2021-10-21       Impact factor: 6.639

5.  Effects of PEG Chain Length on Relaxometric Properties of Iron Oxide Nanoparticles-Based MRI Contrast Agent.

Authors:  Jianxian Ge; Cang Li; Ning Wang; Ruru Zhang; Mohammad Javad Afshari; Can Chen; Dandan Kou; Dandan Zhou; Ling Wen; Jianfeng Zeng; Mingyuan Gao
Journal:  Nanomaterials (Basel)       Date:  2022-08-04       Impact factor: 5.719

Review 6.  Industrialization's eye view on theranostic nanomedicine.

Authors:  Maharajan Sivasubramanian; Li-Jie Lin; Yu-Chao Wang; Chung-Shi Yang; Leu-Wei Lo
Journal:  Front Chem       Date:  2022-08-19       Impact factor: 5.545

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.